Europe Insulin Infusion Pumps Market: Market Size & Forecast 2026

Europe represents one of the most mature insulin pump markets globally, anchored by reimbursement policies in countries such as Germany, France, the Netherlands, Sweden, Switzerland, and the United Kingdom. Insulin infusion pumps account for a focused share of the broader European insulin delivery devices market, which also includes pens, syringes, and jet injectors. Demand is concentrated among type 1 diabetes patients, with growing interest from insulin-intensive type 2 patients as device indications widen.

• •Market size estimated at $1.36 billion in 2025 with an 8.3% CAGR projected to 2030
• •Type 1 diabetes remains the dominant user group, with growing type 2 adoption
• •Western European reimbursement systems support higher pump penetration than Southern and Eastern Europe

Rising diabetes prevalence across Europe remains the principal demand driver, alongside progressive reimbursement expansions that have brought pumps within reach of more patients. Technology improvements, particularly the arrival of hybrid closed-loop and automated insulin delivery systems, are improving clinical outcomes and encouraging switching from multiple daily injections. Greater clinician familiarity and expanded training infrastructure are further accelerating pump starts in routine endocrinology practice.

• •Increasing diabetes prevalence and earlier diagnosis rates across all major European markets
• •Hybrid closed-loop systems improve glycemic control and are driving replacement demand
• •Broader reimbursement coverage for type 2 diabetes patients in selected EU5 countries

The market is typically segmented by product type into tethered pumps and patch/insight pumps, with tethered devices currently holding the larger installed base. End-user segmentation distinguishes between personal use and hospital or clinical use, while the patient segmentation focuses on type 1 versus insulin-dependent type 2 diabetes. Germany, France, the UK, Italy, and Spain form the EU5 core, with the Nordics, Netherlands, and Switzerland also exhibiting notably high per-capita pump adoption.

• •Tethered pumps lead volume, while patch pumps are the fastest-growing product format
• •Germany, France, and the UK contribute the largest absolute revenue in the EU5
• •Nordic countries and the Netherlands show the highest pump penetration rates per diabetes patient

What are the recent trends and outlook?

Hybrid closed-loop systems are moving from premium optionality to default expectation, with reimbursement bodies in major EU markets increasingly covering algorithm-driven pumps. Interoperability and the use of pumps with continuous glucose monitors from different manufacturers are gaining traction, supporting more modular automated insulin delivery configurations. Over the forecast horizon, the market is expected to see continued price discipline, gradual entry of additional closed-loop platforms, and incremental penetration into type 2 diabetes populations.

• •Hybrid closed-loop systems are becoming the standard of care in pump therapy
• •Interoperability between pumps and CGMs is enabling more modular AID setups
• •Type 2 diabetes is emerging as a meaningful incremental patient pool through 2030